Clinical trials: Mucosal Infection
- Condition Mucosal Infection
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
covid19 Infection, Influenza, Human
Covid-19 and Influenza Oral Vaccine Study
The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery.
- Trial name
- NCT06355232
- Testing
- Covid-19 vaccine, Influenza vaccine
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Influenza
A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine
Mucosal-specific sIgA antibody GMT;Evaluate the achievement of 2-fold and 4-fold increases in the geometric mean titer (GMT) of specific nasal mucosal sIgA antibodies after vaccination
- Trial name
- NCT07545564
- Testing
- LAIV
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Influenza Infection
A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult
The objectives of this phase 2 study are to evaluate immunogenicity, safety and tolerability of AD07030, a trivalent influenza virus antigens vaccine, given intranasally in 2 doses in healthy adult volunteers.
- Trial name
- NCT03784885
- Testing
- AD07010, Inactivated trivalent influenza vaccine
- Where
- Taiwan
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Advagene Biopharma Co. Ltd.
HIV Infections, HIV Seronegativity
A Study of GENEVAX-HIV, a Possible Vaccine
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug…
- Trial name
- NCT00002232
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
Upper Respiratory Tract Infections
A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production
A safety study to compare the effect of two different formulations of PrEP-001 nasal powder when dosed in healthy subjects
- Trial name
- NCT03198676
- Testing
- PrEP-001 6.4 mg, PrEP-001 3.2 mg
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Prep Biopharm Limited
COVID-19
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously…
- Trial name
- NCT07215520
- Testing
- NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CastleVax Inc.
Bladder Infections and Inflammations
Chronic Indwelling Foley and Catheter Associated Trauma (CIF-CAT) Study
To determine whether an indwelling low profile Kohli Atraumatic Catheter causes less macro-morphologic inflammation and edema to the bladder mucosa than a traditional indwelling Foley catheter as assess by computerized image…
- Trial name
- NCT03790826
- Testing
- cystoscopy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nellie Medical, LLC
COVID-19
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
One of the current health challenges in the face of the COVID-19 pandemic that started in Wuhan in 2019, and still responsible for successive waves, is to better understand and diagnose the infection.
- Trial name
- COVARIANT (NCT05858502)
- Testing
- Blood sample collection, Saliva sample collection, Nasopharyngeal and nasal sample collection
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Coronavirus Infection, Severe Acute Respiratory Syndrome
Study of the Pathogenesis of Olfactory Disorders in COVID-19
This study is a case-control study to characterize the molecular and cellular anomalies of the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the olfactory epithelium of non-infected subjects.
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome, Sars-CoV2
- Trial name
- COVIDSMELL (NCT04366934)
- Testing
- Nasal swab, Taste and olfactory function evaluation
- Where
- 2 sites in France
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID19, Sars-Cov-2
The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus
COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein.
- Trial name
- COV2NOSE (NCT06851611)
- Testing
- COVID-19 vaccine, low dose level, COVID-19 vaccine, high dose level, Nasal Drops
- Where
- Finland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy
Viral Infections
A Study of Intranasal LMN-1001 in Healthy Adults
The purpose of this study is to optimize the tolerability of LMN-1001 relative to its ability to activate the host immune response. LMN-1001 is an investigational dry powder containing recombinant interferon lambda (IFN-λ).
- Trial name
- NCT07852208
- Testing
- LMN-1001
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.